

**FRONT: References.** 1. World Health Organization. Quantifying selected major risks to health. *The World Health Report 2002: Reducing Risks, Promoting Healthy Life Report*. Geneva, Switzerland: World Health Organization, 2002. <http://www.who.int/whr/2002/chapter4/en/index.html>. Accessed March 24, 2011. 2. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Bethesda, MD: National Institutes of Health; 1998. NIH publication 98-4083. [http://www.nhlbi.nih.gov/guidelines/obesity/ob\\_gdlns.pdf](http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf). Accessed March 24, 2011. 3. Han TS, Tjihuis MA, Lean ME, Seidell JC. Quality of life in relation to overweight and body fat distribution. *Am J Public Health*. 1998;88(12):1814-1820. 4. Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight change and health-related quality of life in women. *JAMA*. 1999;282(22):2136-2142. 5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89(6):2548-2556. 6. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. *Int J Obes*. 2008;32(4):619-628. 7. Després JP, Lemieux S, Lamarche B, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. *Int J Obes Relat Metab Disord*. 1995;19(suppl 1):S75-S86. 8. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343-1350. 9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403. 10. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium restriction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. *Arch Intern Med*. 1997;157(6):657-667. 11. Post RE, Mainous III AG, Gregorie SH, Knoll ME, Diaz VA, Saxena SK. The influence of physician acknowledgement of patients' weight status on patient perceptions of overweight and obesity in the United States. *Arch Int Med*. 2011;171(4):316-321.

**FRONT: References.** 1. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Bethesda, MD: National Institutes of Health; 1998. NIH publication 98-4083. [http://www.nhlbi.nih.gov/guidelines/obesity/ob\\_gdlns.pdf](http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf). Accessed March 24, 2011. 2. Wadden TA, Foster GD. Behavioral treatment of obesity. *Med Clin North Am*. 2000;84(2):441-461. 3. Thomas JG, Wing RR. Maintenance of long-term weight loss. *Med Health R I*. 2009;92. 4. Tate DF, Wing RR, Winnett RA. Using Internet technology to deliver a behavioral weight loss program. *JAMA*. 2001;285(9):1172-1177. 5. Boutelle KN, Kirschenbaum DS. Further support for consistent self-monitoring as a vital component of successful weight control. *Obes Res*. 1998;6(3):219-224. 6. Webber KH, Gabriele JM, Tate DF, Dignan MB. The effect of a motivational intervention on weight loss is moderated by level of baseline controlled motivation. *Int J Behav Nutr Phys Act*. 2010;7:4. 7. Krukowski RA, Harvey-Berino J, Ashikaga T, Thomas CS, Micco N. Internet-based weight control: the relationship between web features and weight loss. *Telemed J E Health*. 2008;14(8):775-782. 8. Hwang KO, Ottenbacher AJ, Green AP, et al. Social support in an Internet weight loss community. *Int J Med Inform*. 2010;79(1):5-13. 9. Harvey-Berino J, Pintauro S, Buzzell P, Gold EC. Effect of internet support on the long-term maintenance of weight loss. *Obes Res*. 2004;12(2):320-329. 10. van den Berg MH, Ronday HK, Peeters AJ, et al. Engagement and satisfaction with an internet-based physical activity intervention in patients with rheumatoid arthritis. *Rheumatology*. 2007;46(3):545-552. 11. Patrick K, Raab F, Adams MA, et al. A text message-based intervention for weight loss: randomized controlled trial. *J Med Internet Res*. 2009;11(1):e1.

**FRONT: References.** 1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89:2548-2556. 2. Beaver JE et al. 1st International Congress on Abdominal Obesity abstracts. CD-ROM Jan 2010. 3. Omnibus Survey, December 2009. 4. Mathieu P, Poirier P, Piabrot P, Lemieux I, Després J-P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. *Hypertension*. 2009;53:577-584. doi: 10.1161/HYPERTENSIONAHA.108.110320. 5. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. *Eur Heart J*. 2009;30:850-856. 6. Haslam D, et al. Managing the overweight/obese patient. *Practice Nurse*. 2008;35(6):26-29. 7. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Bethesda, MD: National Institutes of Health; 1998. NIH publication 98-4083. [http://www.nhlbi.nih.gov/guidelines/obesity/ob\\_gdlns.pdf](http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf). Accessed March 24, 2011. 8. Jacobs EJ, Newton CC, Wang Y, et al. Waist circumference and all-cause mortality in a large US cohort. *Arch Intern Med*. 2010;170(15):1293-1301. 9. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. *Int J Obes*. 2008;32:619-628. 10. Smith SR, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24 week randomized, placebo-controlled, multicenter trial. *Obesity*. In press.

**FRONT: References.** 1. Data on file. GlaxoSmithKline Consumer Healthcare. 2. *Metabolic Disorders Study: Obesity*. Burlington, MA: Decision Resources, LLC; 2011. 3. Xenical Product Information. 4. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. *Drugs*. 2004;64(24):2845-2864. 5. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. *Clin Pharmacol Ther*. 1994;56:82-85. 6. Johnson S, et al. A predictive model for gastrointestinal side effects due to dietary fat with orlistat [abstract 010-27]. 2007 IFT Annual Meeting Technical Program Book of Abstracts; Institute of Food Technologists, Chicago, IL.

**BACK: References.** 1. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Bethesda, MD: National Institutes of Health; 1998. NIH publication 98-4083. [http://www.nhlbi.nih.gov/guidelines/obesity/ob\\_gdlns.pdf](http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf). Accessed March 24, 2011. 2. Jung RT. Obesity as a disease. *Br Med Bull*. 1997;53(2):307-321. 3. Blackburn G. Effect of a degree of weight loss on health benefits. *Obes Res*. 1995;3(suppl 3):211s-216s. 4. Fontaine K, Barofsky I, Anderson RE, et al. Impact of weight loss on health-related quality of life. *Qual Life Res*. 1999;8(3):275-277. 5. Blissmer B, Riebe D, Dye G, Ruggiero L, Greene G, Caldwell M. Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects. *Health and Quality of Life Outcomes*. 2006;4:43. 6. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343-1350. 7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403. 8. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium restriction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. *Arch Intern Med*. 1997;157(6):657-667. 9. Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight change and health-related quality of life in women. *JAMA*. 1999;282(22):2136-2142. 10. Smith SR, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24 week randomized, placebo-controlled, multicenter trial. *Obesity*. In press. 11. Hauptman J, Lucas C, Boldrin MN, Collins H, for the Orlistat Primary Care Study Group, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med*. 2000;9:160-170. 12. Rössner S, Sjöström L, Noack R, Meinders AE, Nosedá G, for the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. *Obes Res*. 2000;8(1):49-61.

**BACK: References.** 1. Greenway F, Smith S, Murray K, et al. Orlistat 60 mg demonstrates a significant reduction in visceral adipose tissue at 24 weeks compared with placebo. Poster presented at: 1st International Congress on Abdominal Obesity, January 2010, Hong Kong, China. 2. Stenlöf K, Greenway F, Smith SR, et al. Significant reduction in body fat assessed by echomri in subjects treated with orlistat 60 mg for 6 months compared with placebo: relationships between changes in body composition and body weight [abstract T3:PO41] *Obes Rev*. 2010(suppl 1):1:235. 3. Smith SR, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24 week randomized, placebo-controlled, multicenter trial. *Obesity*. In press.

**BACK: References.** 1. Johnson S, et al. A predictive model for gastrointestinal side effects due to dietary fat with orlistat [abstract 010-27]. 2007 IFT Annual Meeting Technical Program Book of Abstracts; Institute of Food Technologists, Chicago, IL. 2. all FDA drug facts. 3. *Metabolic Disorders Study: Obesity*. Burlington, MA: Decision Resources, LLC; 2011. 4. Data on file. GlaxoSmithKline Consumer Healthcare.